1. bookVolume 23 (2015): Edition 4 (December 2015)
Détails du magazine
License
Format
Magazine
eISSN
2284-5623
Première parution
08 Aug 2013
Périodicité
4 fois par an
Langues
Anglais
Accès libre

Platinum derivatives: generic brands vs. original, in vitro tests

Publié en ligne: 30 Dec 2015
Volume & Edition: Volume 23 (2015) - Edition 4 (December 2015)
Pages: 439 - 448
Reçu: 08 Jun 2015
Accepté: 24 Sep 2015
Détails du magazine
License
Format
Magazine
eISSN
2284-5623
Première parution
08 Aug 2013
Périodicité
4 fois par an
Langues
Anglais

1. Bertini I, editor. Bioinorganic chemistry. Mill Valley, Calif: University Science Books; 1994. 611 p.Search in Google Scholar

2. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010;39(35):8113. DOI: 10.1039/c0dt00292e10.1039/c0dt00292eSearch in Google Scholar

3. Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol. 2014;15(1):1. DOI: 10.1186/2050-6511-15-110.1186/2050-6511-15-1Search in Google Scholar

4. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002 Jun;42(3):317–25. DOI: 10.1016/S1040-8428(01)00219-010.1016/S1040-8428(01)00219-0Search in Google Scholar

5. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep. 2003 Dec;10(6):1663–82. DOI: 10.3892/or.10.6.166310.3892/or.10.6.1663Search in Google Scholar

6. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000335.jsp&mid=WC-0b01ac0580514d5c.Search in Google Scholar

7. Gallelli L, Mumoli L, Palleria C, Piro B, Russo E, Vasapollo P, et al. Safety and efficacy of generic drugs with respect to brand formulation. J Pharmacol Pharmacother. 2013;4(5):110. DOI: 10.4103/0976-500X.12097210.4103/0976-500X.120972385366224347975Search in Google Scholar

8. Vetchy D, Vetcha M, Rabiskova M, Gryczova E, Bartosikova L. Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug. Med Kaunas Lith. 2007;43(4):326–31.10.3390/medicina43040040Search in Google Scholar

9. Poirier E, Desbiens C, Poirier B, Hogue J-C, Lemieux J, Doyle C, et al. Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients. Ann Pharmacother. 2014 Apr;48(4):447–55. DOI: 10.1177/106002801351494110.1177/106002801351494124321851Search in Google Scholar

10. Tange M, Yoshida M, Nakai Y, Uchida T. Comparison between original and generic versions of ceftriaxone sodium preparation for injection: compatibility with calcium-containing product. Chem Pharm Bull (Tokyo). 2012;60(4):429–34. DOI: 10.1248/cpb.60.42910.1248/cpb.60.42922466725Search in Google Scholar

11. Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Tazuma S. Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2006 Aug;38(8):554–9. DOI: 10.1016/j.dld.2006.01.03210.1016/j.dld.2006.01.03216524789Search in Google Scholar

12. Minzi OMS, Marealle IA, Shekalaghe S, Juma O, Ngaimisi E, Chemba M, et al. Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product. Malar J. 2013;12:174. DOI: 10.1186/1475-2875-12-17410.1186/1475-2875-12-174366961123718725Search in Google Scholar

13. Gasser UE, Fischer A, Timmermans JP, Arnet I. Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®. BMC Pharmacol Toxicol. 2013;14(1):24. DOI: 10.1186/2050-6511-14-2410.1186/2050-6511-14-24364849123617953Search in Google Scholar

14. Sittampalam GS, Coussens NP, Nelson H, Arkin M, Auld D, Austin C, et al., editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004 [cited 2015 May 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK53196/Search in Google Scholar

15. Vanden Berghe T, Grootjans S, Goossens V, Dondelinger Y, Krysko DV, Takahashi N, et al. Determination of apoptotic and necrotic cell death in vitro and in vivo. Methods San Diego Calif. 2013 Jun 1;61(2):117–29. DOI: 10.1016/j.ymeth.2013.02.01110.1016/j.ymeth.2013.02.01123473780Search in Google Scholar

16. Krysko DV, Vanden Berghe T, D’Herde K, Vandenabeele P. Apoptosis and necrosis: Detection, discrimination and phagocytosis. Methods. 2008 Mar;44(3):205–21. DOI: 10.1016/j.ymeth.2007.12.00110.1016/j.ymeth.2007.12.00118314051Search in Google Scholar

17. Chang Y-J, Huang C-Y, Hung C-S, Chen W-Y, Wei P-L. GRP78 mediates the therapeutic efficacy of curcumin on colon cancer. Tumor Biol. 2015 Feb;36(2):633–41. DOI: 10.1007/s13277-014-2640-310.1007/s13277-014-2640-325277658Search in Google Scholar

18. Liou J-Y, Aleksic N, Chen S-F, Han T-J, Shyue S-K, Wu KK. Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. Exp Cell Res. 2005 May 15;306(1):75–84. DOI: 10.1016/j. yexcr.2005.01.011Search in Google Scholar

19. Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M. Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells. Yeudall A, editor. PLoS ONE. 2014 Apr 23;9(4):e94621.10.1371/journal.pone.0094621399740324760019Search in Google Scholar

20. Rasul KI, Kamal AS, Al-Najjar NM, Oculalan MH. Is there a Diference between Brand and Generic Oxaliplatin? Cancer Clin Oncol [Internet]. 2012 Jun 18 [cited 2015 Apr 30];1(2). Available from: http://www.ccsenet.org/journal/index.php/cco/article/view/1815710.5539/cco.v1n2p45Search in Google Scholar

21. Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important? BMJ. 2001 Jun 23;322(7301):1536–8. DOI: 10.1136/bmj.322.7301.153610.1136/bmj.322.7301.1536112057611420279Search in Google Scholar

22. Florea A-M, Büsselberg D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers. 2011 Mar 15;3(4):1351–71. DOI: 10.3390/cancers301135110.3390/cancers3011351375641724212665Search in Google Scholar

23. Henry CM, Hollville E, Martin SJ. Measuring apoptosis by microscopy and flow cytometry. Methods. 2013 Jun;61(2):90–7. DOI: 10.1016/j.ymeth.2013.01.00810.1016/j.ymeth.2013.01.00823403105Search in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo